ArticleScientific reports2018
Inhibition and Eradication of Pseudomonas aeruginosa Biofilms by Host Defence Peptides.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 81 citations in OpenAlex.
- Pepholin, a bacteriophage holin-derived antimicrobial peptide with membrane-disruptive activity and therapeutic efficacy in MDRRSC advances · 2026Article
- Chemical profile, anti-biofilm and antioxidant activities of Cymbopogon citratus (DC.) Stapf essential oil.BMC complementary medicine and therapies · 2026Article
- Bioactive metabolites of UV-resistant Streptomyces alkaliterrae CH-8 and their antioxidant and antibiofilm potential.Scientific reports · 2026Article
- Mapping the knowledge landscape ofFrontiers in cellular and infection microbiology · 2026Review
- Designing, Synthesis and In Vitro Antimicrobial Activity of Peptide Against Biofilm Forming Methicillin Resistant Staphylococcus aureus.Current microbiology · 2025Article
- Effect of Candida albicans' supernatant on biofilm formation and virulence factors of Pseudomonas aeruginosa through las/rhl System.BMC microbiology · 2025Article
- Comparative evaluation of antimicrobial peptides: effect on formation, metabolic activity and viability ofFrontiers in microbiology · 2025Article
- Conjugation of CRAMPInternational journal of molecular sciences · 2024Article
- Exploring the Potential of Halotolerant Actinomycetes from Rann of Kutch, India: A Study on the Synthesis, Characterization, and Biomedical Applications of Silver Nanoparticles.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Effect of baicalin on eradicating biofilms of bovine milk derived Acinetobacter lwoffii.BMC veterinary research · 2024Article
- Comparison Between Moxifloxacin and Chloramphenicol for the Treatment of Bacterial Eye Infections.Current therapeutic research, clinical and experimental · 2024Article
- Phenotypic and genetic characterization of daptomycin non-susceptibleFrontiers in cellular and infection microbiology · 2024Article
- Effects of synthetic peptide RP557 and its origin, LL-37, on carbapenem-resistantMicrobiology spectrum · 2023Article
- Antimicrobial Peptides Originating from Expression Libraries ofMicroorganisms · 2023Article
- Inhibition and eradication ofRSC medicinal chemistry · 2023Article
- A Novel Generation of Tailored Antimicrobial Drugs Based on Recombinant Multidomain Proteins.Pharmaceutics · 2023Article
- Combined Use of Antimicrobial Peptides with Antiseptics against Multidrug-Resistant Bacteria: Pros and Cons.Pharmaceutics · 2023Article
- Sensor histidine kinasesFrontiers in cellular and infection microbiology · 2023Article
- Anti-Virulence Potential of a Chionodracine-Derived Peptide against Multidrug-ResistantInternational journal of molecular sciences · 2022Article
- Pseudomonas aeruginosa biofilm dispersion by the mouse antimicrobial peptide CRAMP.Veterinary research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
P. aeruginosa is a notorious biofilm producer that causes a wide variety of acute and chronic infections. In this study the in vitro anti-biofilm activity of 13 Host Defence Peptides from different species was tested against P. aeruginosa biofilms. Most HDPs were able to prevent biofilm attachment, due to their antimicrobial effect on planktonic bacteria in the starting inoculum. Activity of HDPs against pre-formed biofilms was also observed, although mainly at short incubation times. Several HDPs were able to kill bacteria in the biofilm (colony counting of biofilm associated bacteria) but only CRAMP eradicated the whole biofilm (crystal violet staining). These results were quantitatively confirmed by confocal microscopy studies using a live/dead stain of the biofilms. Furthermore, for chicken CATH-2 (one of the more potent HDPs) it was shown that the peptide could indeed penetrate the biofilm structures and kill bacteria within the biofilm. These studies highlight the potency but also the limitations of HDPs as new potential anti-biofilm agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.